Ozmen Rifat, Uysal Cihan, Herdem Nevzat, Ipekten Funda, Gunturk Inayet, Tuncay Aydin, Ozocak Okan, Yazici Cevat, Kocyigit Ismail
Department of Cardiovasculary Surgery, Erciyes University School of Medicine, Kayseri, Turkey.
Department of Nephrology, Erciyes University School of Medicine, Dede Efendi Street, Köşk, Melikgazi, PC 38030, Kayseri, Turkey.
Clin Exp Nephrol. 2025 Mar 19. doi: 10.1007/s10157-025-02655-2.
Gelsolin is a key regulator of actin filament metabolism and plays a role in tissue remodeling. We evaluated plasma gelsolin (pGSN) in predicting arteriovenous fistula (AVF) maturation.
Only patients with newly created radiocephalic AVF were included. pGSN and plasma F-actin levels were measured preoperatively. Maturation was defined as an access (cephalic) vein diameter > 5 mm and a fistula blood flow rate > 500 mL/min in ultrasound, 8 weeks after operation.
A total of 68 patients were analyzed with a mean age of 62.6 ± 11.1 years. AVF maturation was identified in 39 patients (57.3%). Mean pGSN level was 4726 (3836-6483) ng/mL in patients with mature AVF and 3237 (2895-4382) ng/mL in patients with immature AVF. pGSN levels were significantly higher (p < 0.001) in the mature AVF group. F-actin levels were not significantly different between two groups. pGSN levels positively correlated with fistula blood flows (r = 0.326, p = 0.007). Multivariate logistic regression analysis revealed that pGSN (p = 0.003) was determined to be an independent risk factor in predicting AVF maturation. Preoperative pGSN levels were significantly predictive of AVF maturation in the ROC analysis. Sensitivity and specificity of pGSN were 82.1% and 58.6%, respectively, with a cut-off value of > 3716 ng/mL and an area under the ROC curve of 0.75 (95% CI: 0.64-0.87, p < 0.001).
Current results demonstrated that patients with mature AVFs had significantly higher preoperative pGSN levels compared to those with immature AVFs. Outcomes suggest that pGSN could serve as a predictive biomarker for AVF maturation.
凝溶胶蛋白是肌动蛋白丝代谢的关键调节因子,在组织重塑中发挥作用。我们评估了血浆凝溶胶蛋白(pGSN)在预测动静脉内瘘(AVF)成熟方面的作用。
仅纳入新建立桡动脉-头静脉内瘘的患者。术前测量pGSN和血浆F-肌动蛋白水平。成熟定义为术后8周超声检查时,吻合口(头静脉)直径>5mm且内瘘血流量>500mL/min。
共分析68例患者,平均年龄62.6±11.1岁。39例患者(57.3%)的AVF成熟。成熟AVF患者的平均pGSN水平为4726(3836 - 6483)ng/mL,未成熟AVF患者为3237(2895 - 4382)ng/mL。成熟AVF组的pGSN水平显著更高(p<0.001)。两组间F-肌动蛋白水平无显著差异。pGSN水平与内瘘血流量呈正相关(r = 0.326,p = 0.007)。多因素逻辑回归分析显示,pGSN(p = 0.003)被确定为预测AVF成熟的独立危险因素。在ROC分析中,术前pGSN水平对AVF成熟具有显著预测价值。pGSN的敏感性和特异性分别为82.1%和58.6%,截断值>3716 ng/mL,ROC曲线下面积为0.75(95%CI:0.64 - 0.87,p<0.001)。
目前的结果表明,与未成熟AVF患者相比,成熟AVF患者术前的pGSN水平显著更高。结果提示pGSN可作为AVF成熟的预测生物标志物。